Literature DB >> 22187937

Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs.

Demetrios Vlahakos1, Nikolaos Arkadopoulos, Georgia Kostopanagiotou, Sofia Siasiakou, Loukas Kaklamanis, Dimitrios Degiannis, Maria Demonakou, Vassilios Smyrniotis.   

Abstract

We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI). The purpose of this research was to study if DFO could attenuate sepsis inflammatory response syndrome (SIRS) and confer renoprotection in the same model of AHI in anesthetized pigs. Fourteen animals were randomly allocated to two groups. In the Group DFO (n=7), 150mg/kg of DFO dissolved in normal saline was continuously infused in animals undergoing hepatic devascularization and portacaval anastomosis. The control group (Group C, n=7) underwent the same surgical procedure and received the same volume of normal saline infusion. Animals were euthanized after 24h. Hematological, biochemical parameters, malondialdehyde (MDA), and cytokines (interleukin [IL]-1β, IL-6, IL-8, IL-10, and tumor necrosis factor-α) were determined from sera obtained at baseline, at 12h, and after euthanasia. Hematoxylin-eosin and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling were used to evaluate necrosis and apoptosis, respectively, in kidney sections obtained after euthanasia. A rapid and substantial elevation (more than 100-fold) of serum IL-6 levels was observed in Group C reaching peak at the end of the experiment, associated with increased production of oxygen free radicals and lipid peroxidation (MDA 3.2±0.1nmol/mL at baseline and 5.5±0.9nmol/mL at the end of the experiment, P<0.05) and various manifestations of SIRS and multiple organ dysfunction (MOD), including elevation of high-sensitivity C-reactive protein, severe hypotension, leukocytosis, thrombocytopenia, hypoproteinemia, and increased serum levels of lactate dehydrogenase (fourfold), alkaline phosphatase (fourfold), alanine aminotransferase (14-fold), and ammonia (sevenfold). In sharp contrast, IL-6 production and lipid peroxidation were completely blocked in DFO-treated animals offering remarkable resistance to the development of SIRS and MOD. Profound proteinuria, strips of extensive necrosis of tubular epithelial cells, and occasional apoptotic tubular epithelial cells were already present in Group C, but not in Group DFO animals at the time of euthanasia. DFO infusion attenuated lipid peroxidation, blocked IL-6 production, and substantially diminished SIRS and MOD, including tubulointerstitial damage in pigs after acute ischemic hepatic failure. This finding shows that iron, IL-6, and lipid peroxidation are important participants in the pathophysiology of renal injury in the course of generalized inflammation and provides novel pathways of therapeutic interventions for renal protection.
© 2011, Copyright the Authors. Artificial Organs © 2011, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22187937     DOI: 10.1111/j.1525-1594.2011.01385.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  13 in total

1.  Effect of N-acetylcysteine plus deferoxamine on oxidative stress and inflammation in dystrophic muscle cells.

Authors:  Luis Henrique Rapucci Moraes; Roberta Constâncio Bollineli; Daniela Sayuri Mizobuti; Leonardo Dos Reis Silveira; Maria Julia Marques; Elaine Minatel
Journal:  Redox Rep       Date:  2014-10-31       Impact factor: 4.412

Review 2.  Iron Chelation as a Potential Therapeutic Strategy for AKI Prevention.

Authors:  Shreyak Sharma; David E Leaf
Journal:  J Am Soc Nephrol       Date:  2019-09-25       Impact factor: 10.121

3.  Deferoxamine: emerging, new neuro-protective benefits.

Authors:  Shailendra Kapoor
Journal:  Neurol Sci       Date:  2013-04-23       Impact factor: 3.307

4.  Emerging Role for Ferroptosis in Infectious Diseases.

Authors:  Eduardo Pinheiro Amaral; Sivaranjani Namasivayam
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.

Authors:  Mark Laws; Yasmin M Surani; Md Mahbub Hasan; Yiyuan Chen; Peiqin Jin; Taha Al-Adhami; Madiha Chowdhury; Aqeel Imran; Ioannis Psaltis; Shirin Jamshidi; Kazi S Nahar; Khondaker Miraz Rahman
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

Review 6.  The Cross-Link between Ferroptosis and Kidney Diseases.

Authors:  Jingyu Wang; Yi Liu; Yaqing Wang; Li Sun
Journal:  Oxid Med Cell Longev       Date:  2021-05-03       Impact factor: 6.543

Review 7.  The utility of iron chelators in the management of inflammatory disorders.

Authors:  C Lehmann; S Islam; S Jarosch; J Zhou; D Hoskin; A Greenshields; N Al-Banna; N Sharawy; A Sczcesniak; M Kelly; K Wafa; W Cheliak; B Holbein
Journal:  Mediators Inflamm       Date:  2015-03-23       Impact factor: 4.711

8.  Redox signaling pathways involved in neuronal ischemic preconditioning.

Authors:  John W Thompson; Srinivasan V Narayanan; Miguel A Perez-Pinzon
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

9.  Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma.

Authors:  Haim Bibi; Vladimir Vinokur; Dan Waisman; Yigal Elenberg; Amir Landesberg; Anna Faingersh; Moran Yadid; Vera Brod; Jimy Pesin; Eduard Berenshtein; Ron Eliashar; Mordechai Chevion
Journal:  Redox Biol       Date:  2014-06-18       Impact factor: 11.799

10.  Lung injury induced by short-term mechanical ventilation with hyperoxia and its mitigation by deferoxamine in rats.

Authors:  Xiao-Xia Wang; Xiao-Lan Sha; Yu-Lan Li; Chun-Lan Li; Su-Heng Chen; Jing-Jing Wang; Zhengyuan Xia
Journal:  BMC Anesthesiol       Date:  2020-08-01       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.